65,437 trials
BRCA1 Mutation Carrier · BRCA2 Mutation Carrier · Ovarian Epithelial Tumor
Primary: Proportion of Patients With Complete and Partial Tumor Response — 0.26 Proportion of patients
Ulcerative Colitis Associated Pouchitis
Primary: Number of Patients Who Experienced Improvement of Pouchitis Symptoms — 2 Participants
COPD
Primary: Specific Airway Volume (siVaw) — 1.79; 1.02 mL/L — p=<0.0001
Non-Alcoholic Steatohepatitis
Primary: Number of Participants With Biopsy Proven Non-Alcoholic Steatohepatitis — 74; 20; 13 Participants
Onychomycosis · Dermatophytosis
Primary: Number of Participants With Elimination of Dermatophytomas That Occur in Distal Lateral Subungual Onychomycosis (DLSO) — 19 Participants
Obesity
Primary: Change in Oxidative Stress: Baseline to 2 Hours — -0.003; -0.006; 0.01; -0.006 pg /ml
Rheumatoid Arthritis
Primary: Number and Percent of Participants With Reduction of Immunity to Collagen Type-II After APLA-12 Treatment. — 9; 4 Participants — p=0.5179
Primary Sjögren's Syndrome
Primary: Change From Baseline in European League Against Rheumatism Sjogren's Syndrome Disease Activity Index (ESSDAI) Score at Day 99 — -2.3; -3.8 Scores on a scale — p=0.262
Sleep Apnea Syndromes
Primary: Average Apnea Hypopnea Index Among Different Polysomnography Devices. — 18.4; 25.4; 24.1; 19.2 events per hour
Lymphoma
Primary: Event-Free Survival (EFS) - Intent-to-Treat (ITT) Population — 49.64; 54.77 Months — p=0.5167
Nicotine Addiction
Primary: Resisting Smoking - Time to First Cigarette in the Resist Smoking Paradigm — 60.3; 63.4; 63.2 minutes — p=0.94
Correction of Nasolabial Folds
Primary: Incidence of Device-related Adverse Events — 3 Participants
COPD Exacerbation
Primary: The Difference Between the Values of Area Under the Response Curve for FEV1 — 203.0; 185.0 mcg*hr/mL
Peripheral Arterial Disease
Primary: Device Technical Success — 29 lesions
Hypercholesterolemia
Primary: Number of Participants With Adverse Events — 526; 415; 206; 38 Participants